PHARMACEUTICAL TECHNOLOGY INDEX 1985

AUTHORS

Anderson, N.R.; Anderson, R.L.; and Taber, M.R. Computerspeak. Monthly column. Jan.–Dec.

Anderson, R.L. See Anderson, N.R.

Baichwal, Anand R.; and Shangraw, Ralph F. Tableting properties of a new protein/lactose/mineral complex. Sept., p. 44.

Barker, J.F. See Jones, Trevor M.

Batuyios, N.H. See Gore, A.Y.

Benrimoj, S.I. A look at OTC buying habits. March, p. 24.

Brady, Edward S. No need to apologize. June, p. 18.

Burt, R.A.P. The good side of side effects. Nov., p. 20.

Chapman, Ken. It's our move. May, p. 16.

Chapman, Ken. See PMA's Deionized Water Committee.

Chapman, Ken. See PMA's Validation Advisory Committee.

Chi, Li-hua. See Chowhan, Z.T.

Chiang, C.C. See Hsieh, Dean S.T.

Chien, Te-yen; and Nuessle, Noel O. Factors influencing migration during spheronization. April, p. 42.

Chien, Yie W. The use of biocompatible polymers in rate-controlled drug delivery systems. May, p. 50.

Chowhan, Z.T.; and Chi, Li-hua. Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. March, p. 84.

Chowhan, Z.T.; and Chi, Li-hua. Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. April, p. 28.

Chu, Peter K.; and Marino, Frank J. A method for the production of *Clostridium sporogenes* PA 3679 spores on solid medium. Dec., p. 36.

Davis, Priscilla J. See Lacy, Mark E.

Dean, D.A. Sources of particulate contamination in sterile packaging. Aug., p. 32.

Desai, D.S. See Hsieh, Dean S.T.

Dickinson, James. Washington Report. Monthly column. Jan.–Dec.

Doyle, Thomas D.; and Wainer, Irving W. The resolution of enantiomeric drugs using HPLC chiral stationary phases. Feb., p. 28.

Ehrhardt, L. See Köblitz, T.

Farnsworth, Norman. An old source of new drugs. Aug., p. 14.

Fletcher, P.M. See Rangwalla, I.J.

Fraade, David J. Automation: a retrospective look. Feb., p. 16.

Giannini, Robert P. Acquiring and using data in studies of compaction. Feb., p. 44.

Gore, A.Y.; McFarland, D.W.; and Batuyios, N.H. Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. Sept., p. 114.

Heckler, Margaret M. FDA's new action plan. Sept., p. 18.

Ho, A.Y.K. See Jones, Trevor M.

Hsieh, Dean S.T.; Chiang, C.C.; and Desai, D.S. Controlled release of macromolecules from silicone elastomer. June, p. 39.

Johnson, Earl S. See Lacy, Mark E.

Jones, B.E. Hard gelatin capsules and the pharmaceutical formulator. Sept., p. 106.

Jones, David M. Factors to consider in fluid-bed processing. April, p. 50.

Jones, David M. See Mehta, Atul M.

Jones, Trevor M.; Ho, A.Y.K.; and Barker, J.F. The use of instrumentation in tablet research, development, and production. March, p. 42.

Joslin, Robert S. The coming crisis in pharmaceutical development. Dec., p. 48.

Kastury, Uma. See Kushnir, Joel.

Kaul, M. Electrical design in clean rooms. Dec., p. 40.

Kelley, Glenn A. FDA guidelines for the inspection of bulk pharmaceutical chemicals. Oct., p. 32.

Köblitz, T.; Ehrhardt, L.; and Körblein, Günter. Continuous variable-frequency fluid-bed drying of pharmaceutical granulations. March, p. 62.

Koester, Ann P. See Lacy, Mark E.

Körblein, Günter. See Köblitz, T.

Kushnir, Joel; Kastury, Uma; and Shabica, Anthony. Product tampering: an update on minimizing risks. Feb., p. 48.

Kuzel, Norbert R. Fundamentals of computer system validation and

PHARMACEUTICAL TECHNOLOGY INDEX 1985

AUTHORS

Anderson, N.R.; Anderson, R.L.; and Taber, M.R. Computerspeak. Monthly column. Jan.–Dec.

Anderson, R.L. See Anderson, N.R.

Baichwal, Anand R.; and Shangraw, Ralph F. Tableting properties of a new protein/lactose/mineral complex. Sept., p. 44.

Barker, J.F. See Jones, Trevor M.

Batuyios, N.H. See Gore, A.Y.

Benrimoj, S.I. A look at OTC buying habits. March, p. 24.

Brady, Edward S. No need to apologize. June, p. 18.

Burt, R.A.P. The good side of side effects. Nov., p. 20.

Chapman, Ken. It's our move. May, p. 16.

Chapman, Ken. See PMA's Deionized Water Committee.

Chapman, Ken. See PMA's Validation Advisory Committee.

Chi, Li-hua. See Chowhan, Z.T.

Chiang, C.C. See Hsieh, Dean S.T.

Chien, Te-yen; and Nuessle, Noel O. Factors influencing migration during spheronization. April, p. 42.

Chien, Yie W. The use of biocompatible polymers in rate-controlled drug delivery systems. May, p. 50.

Chowhan, Z.T.; and Chi, Li-hua. Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. March, p. 84.

Chowhan, Z.T.; and Chi, Li-hua. Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. April, p. 28.

Chu, Peter K.; and Marino, Frank J. A method for the production of *Clostridium sporogenes* PA 3679 spores on solid medium. Dec., p. 36.

Davis, Priscilla J. See Lacy, Mark E.

Dean, D.A. Sources of particulate contamination in sterile packaging. Aug., p. 32.

Desai, D.S. See Hsieh, Dean S.T.

Dickinson, James. Washington Report. Monthly column. Jan.–Dec.

Doyle, Thomas D.; and Wainer, Irving W. The resolution of enantiomeric drugs using HPLC chiral stationary phases. Feb., p. 28.

Ehrhardt, L. See Köblitz, T.

Farnsworth, Norman. An old source of new drugs. Aug., p. 14.

Fletcher, P.M. See Rangwalla, I.J.

Fraade, David J. Automation: a retrospective look. Feb., p. 16.

Giannini, Robert P. Acquiring and using data in studies of compaction. Feb., p. 44.

Gore, A.Y.; McFarland, D.W.; and Batuyios, N.H. Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. Sept., p. 114.

Heckler, Margaret M. FDA's new action plan. Sept., p. 18.

Ho, A.Y.K. See Jones, Trevor M.

Hsieh, Dean S.T.; Chiang, C.C.; and Desai, D.S. Controlled release of macromolecules from silicone elastomer. June, p. 39.

Johnson, Earl S. See Lacy, Mark E.

Jones, B.E. Hard gelatin capsules and the pharmaceutical formulator. Sept., p. 106.

Jones, David M. Factors to consider in fluid-bed processing. April, p. 50.

Jones, David M. See Mehta, Atul M.

Jones, Trevor M.; Ho, A.Y.K.; and Barker, J.F. The use of instrumentation in tablet research, development, and production. March, p. 42.

Joslin, Robert S. The coming crisis in pharmaceutical development. Dec., p. 48.

Kastury, Uma. See Kushnir, Joel.

Kaul, M. Electrical design in clean rooms. Dec., p. 40.

Kelley, Glenn A. FDA guidelines for the inspection of bulk pharmaceutical chemicals. Oct., p. 32.

Köblitz, T.; Ehrhardt, L.; and Körblein, Günter. Continuous variable-frequency fluid-bed drying of pharmaceutical granulations. March, p. 62.

Koester, Ann P. See Lacy, Mark E.

Körblein, Günter. See Köblitz, T.

Kushnir, Joel; Kastury, Uma; and Shabica, Anthony. Product tampering: an update on minimizing risks. Feb., p. 48.

Kuzel, Norbert R. Fundamentals of computer system validation and



documentation in the pharmaceutical industry. Sept., p. 60.
Lacy, Mark E.; Davis, Priscilla J.; Johnson, Earl S.; and Koester, Ann P. Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. March, p. 98.
Langer, Robert. Biomaterials: new perspectives on their use in the controlled delivery of polypeptides. Oct., p. 35.
Levy, Richard A. Weighing the costs of novel drug delivery. Oct., p. 16.
Littman, H. An overview of flow regimes in fluidized beds. March, p. 48.
Liu, Darrell T. See Noguchi, Philip D.
Marino, Frank J. See Chu, Peter K.
McFarland, D.W. See Gore, A.Y.
Mead, William J. Proper maintenance: a key to product quality. Oct., p. 42.
Mehta, Atul M.; and Jones, David M. Coated pellets under the microscope. June, p. 52.
Michels, Daniel L. FDA update: a summary of recent trends in the regulation of drug manufacturing. March, p. 108.
Nablo, S.V. See Rangwalla, I.J.
Noguchi, Philip D.; and Liu, Darrell T. Research and regulatory programs for products derived from rDNA technology. Oct., p. 48.
Nuessle, Noel O. See Chien, Te-yen.
PMA's Deionized Water Committee. Validation and control concepts for water treatment systems. Nov., p. 50.
PMA's Joint Committee on Bioavailability. The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. June, p. 62.
PMA's Reprocessing Committee. Concepts for reprocessing drug products. Sept., p. 127.
PMA's Validation Advisory Committee. Process validation concepts for drug products. Sept. p. 78.
Pondell, Ralph. Scale-up of film coating processes. June, p. 68.
Rangwalla, I.J.; Fletcher, P.M.; Williams, K.E.; and Nablo, S.V. Electron-beam sterilization and its application to aseptic packaging. Nov., p. 36.
Regnier, Fred E. Chromatographic purification of biopolymers. Aug., p. 26.
Renner, Kevyn. Development of an automation plan for a pharmaceutical manufacturing plant. Dec., p. 24.
Roeloffs, Edward. Electrical specifications for pharmaceutical manufacturing equipment. Jan., p. 32.
Seager, H. Soft gelatin capsules: a solution to many tableting problems. Sept., p. 84.
Shabica, Anthony. See Kushnir, Joel.
Shangraw, Ralph F. See Baichwal, Anand R.
Smith, R.J. Pneumatic logic systems and their application in the pharmaceutical industry. Feb., p. 34.
Stetler, C. Joseph. It's time for some good news about drugs. April, p. 18.
Stockdale, D.P. Design and operation of an aseptic filling system. May, p. 38.
Taber, M.R. See Anderson, N.R.
Tucker, Ian. Nonisothermal stability testing. May, p. 68.
Urquhart, John. The unfulfillable promise of safety. Dec., p. 14.
Vickory, Harriet. See PMA's Reprocessing Committee.
Wainer, Irving W. See Doyle, Thomas D.
Williams, K.E. See Rangwalla, I.J.
Young, Frank E. Facing the twenty-first century. Jan., p. 16.

SUBJECTS

ADVERTISING (see also DRUG MARKETING)
"Art Hayes was wrong," in Washington Report. James Dickinson. Jan., p. 18.

AMERICAN PHARMACEUTICAL ASSOCIATION (APhA)
"Bridge to discord," in Washington Report. James Dickinson. May, p. 20.
"Pharmacy's growing power," in Washington Report. James Dickinson. Aug., p. 16.

ABBREVIATED NDAs (see NDAs)

ASSAY AND BIOASSAY METHODS
Controlled release of macromolecules from silicone elastomer. Dean S.T. Hsieh, C.C. Chiang, and D.S. Desai. June, p. 39.
The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. PMA's Joint Committee on Bioavailability. June, p. 62.

AUTOMATION
Automation: a retrospective look. David J. Fraade. Feb., p. 16.
Computerspeak. Monthly column. Jan.–Dec.
Development of an automation plan for a pharmaceutical manufacturing plant. Kevyn Renner. Dec., p. 24.
FDA update: a summary of recent trends in the regulation of drug manufacturing. Daniel L. Michels. March, p. 108.
Fundamentals of computer system validation and documentation in the pharmaceutical industry. Norbert R. Kuzel. Sept., p. 60.
Pneumatic logic systems and their application in the pharmaceutical industry. R.J. Smith. Feb., p. 34.

BIOAVAILABILITY
Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.
Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.
The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. PMA's Joint Committee on Bioavailability. June, p. 62.
Soft gelatin capsules: a solution to many tableting problems. H. Seager. Sept., p. 84.
The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.

BIOEQUIVALENCE
"Citizen's petition," in Washington Report. James Dickinson. May, p.20.
The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. PMA's Joint Committee on Bioavailability. June, p. 62.

BIOTECHNOLOGY
Biomaterials: new perspectives on their use in the controlled delivery of polypeptides. Robert Langer. Oct., p. 35.
Research and regulatory programs for products derived from rDNA technology. Philip D. Noguchi and Darrell T. Liu. Oct., p. 48.

BOOK REVIEWS
Anderson, J.M., and Kim, S.W., eds., *Recent Advances in Drug Delivery Systems*, reviewed by Michael J. Groves. Sept., p. 150.
Avis, Kenneth E., Lachman, Leon, and Lieberman, Herbert A., eds., *Pharmaceutical Dosage Forms: Parenteral Medication, Volume 1*, reviewed by Patrick Belcastro. March, p. 134.
Barber, Michael S., and Barnacal, Pamela A., *Better Pills — The Right Kind of Medicine*, reviewed by Michael J. Groves. Sept., p. 147.
Becher, Paul, ed., *Encyclopedia of Emulsion Technology: Volume 1: Basic Theory*, reviewed by Michael J. Groves. June, p. 74.
Bolton, Sanford, *Pharmaceutical Statistics: Practical and Clinical Applications*, reviewed by Sharon Anderson. Sept. p. 149.
Heilmann, Klaus, and Urquhart, John, *Risk Watch: The Odds of Life*, reviewed by Michael J. Groves. March, p. 128.
Heilmann, Klaus, *Therapeutic Systems Rate-Controlled Drug Delivery:*

Concept and Development, reviewed by Michael J. Groves. Sept., p. 146.
Jones, D.A., ed., *Transdermal and Related Drug Delivery Systems*, reviewed by Michael J. Groves. March, p. 134.
Loftus, Bernard T., and Nash, Robert A., *Pharmaceutical Process Validation*, reviewed by Carl B. Rifino. Oct., p. 52.
Mandelbrot, Benoit B., *The Fractal Geometry of Nature*, reviewed by Michael J. Groves. March, p. 128.
Shapley, Deborah, and Roy, Rustium, *Lost at the Frontier: U.S. Science and Technology Policy Adrift*, reviewed by Michael J. Groves, Sept., p. 144.
Smolen, Victor F., and Ball, Lu Ann, eds., *Controlled Drug Bioavailability, Volume 1: Drug Product Design and Performance, and Volume 2: Bioavailability Methodology and Regulation*, reviewed by Michael J. Groves, March, p. 132.
Smolen, Victor F., and Ball, Lu Ann, eds., *Controlled Drug Bioavailability, Volume 3: Bioavailability Control by Drug Delivery System Design*, reviewed by Michael J. Groves. Sept., p. 144.

BULK PHARMACEUTICAL CHEMICALS
Concepts for reprocessing drug products. PMA's Reprocessing Committee. Sept., p. 127.
FDA guidelines for the inspection of bulk pharmaceutical chemicals. Glenn A. Kelley. Oct., p. 32.

CAPSULES
Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. Mark E. Lacy, Priscilla J. Davis, Earl S. Johnson, and Ann P. Koester. March, p. 98.
Hard gelatin capsules and the pharmaceutical formulator. B.E. Jones. Sept., p. 106.
Soft gelatin capsules: a solution to many tableting problems. H. Seager. Sept., p. 84.

CHROMATOGRAPHY
Chromatographic purification of biopolymers. Fred E. Regnier. Aug., p. 26.
The resolution of enantiomeric drugs using HPLC chiral stationary phases. Thomas D. Doyle and Irving W. Wainer. Feb., p. 28.

COATING
Coated pellets under the microscope. Atul M. Mehta and David M. Jones. June, p. 52.
Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.
Scale-up of film coating processes. Ralph Pondell. June, p. 68.

COMPRESSION/COMPACTION
Acquiring and using data in studies of compaction. Robert P. Giannini. Feb., p. 44.
Soft gelatin capsules: a solution to many tableting problems. H. Seager. Sept., p. 84.
Tableting properties of a new protein/lactose/mineral complex. Anand R. Baichwal and Ralph F. Shangraw. Sept., p. 44.
The use of instrumentation in tablet research, development, and production. Trevor M. Jones, A.Y.K. Ho, and J.F. Barker. March, p. 42.

COMPUTERS (see AUTOMATION)

CONTAMINATION
Design and operation of an aseptic filling system. D.P. Stockdale. May, p. 38.
Sources of particulate contamination in sterile packaging. D.A. Dean. Aug., p. 32.

CONTROLLED RELEASE (see also DRUG DELIVERY)
Biomaterials: new perspectives on their use in the controlled delivery of polypeptides. Robert Langer. Oct., p. 35.
Controlled release of macromolecules from silicone elastomer. Dean S.T. Hsieh, C.C. Chiang, and D.S. Desai. June, p. 39.
The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.
Weighing the costs of novel drug delivery. Richard A. Levy. Oct., p. 16.

Circle Reader Service Card No. 26→


Clean Space Invaders...
araclean
The clean room garment professionals™
ARACLEAN SERVICES, INC.
Marketing Headquarters
One North Beacon St.
La Grange, IL 60525
Offices and plants coast to coast.
Tyvek is the registered trade mark of E. I. DuPont De Nemours.
© ARACLEAN SERVICES, INC. 1985

CUSTOM CHEMICALS
UNBEATABLE QUALITY!

MOLECULES
MADE TO ORDER

YOUR MARK OF
EXCELLENCE FOR
CUSTOM CHEMICALS

Rütgers

Whenever you need a supplementary - or primary - high-quality manufacturing source for bulk pharmaceuticals, specialty chemicals or intermediates, we hope you'll think of Ruetgers-Nease.

We're reliable, and fully experienced in a wide range of reactions. Our equipment includes glass and stainless steel reactors, centrifuges, filters and dryers. And we pride ourselves on our strict adherence to all government regulations.

Call or write today to arrange a conference in your offices or ours on how we can meet your custom production needs.

Contact Dr. John Wetzel, Director of Commercial Development

Ruetgers-Nease
Chemical Company, Inc.

201 Struble Road, State College, Pennsylvania 16801
(814) 238-2424 TWX No. 5106703533

At Ruetgers-Nease, we do custom chemicals uncommonly well.

Circle Reader Service Card No. 27

COST CONTAINMENT

"In defense of AWP," in Washington Report. James Dickinson. Aug., p.16.

"Pharmacy's growing power," in Washington Report. James Dickinson. Aug., p. 16.

"Trouble at HHS," in Washington Report. James Dickinson. Dec., p. 16.

Weighing the costs of novel drug delivery. Richard A. Levy. Oct., p. 16.

DISINTEGRATION

Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.

Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.

Factors influencing migration during spheronization. Te-yen Chien and Noel O. Nuessle. April, p. 42.

DISSOLUTION

Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.

Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.

The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. PMA's Joint Committee on Bioavailability. June, p. 62.

DRUG DELIVERY (see also CONTROLLED RELEASE)

Biomaterials: new perspectives on their use in the controlled delivery of polypeptides. Robert Langer. Oct., p. 35.

The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.

Weighing the costs of novel drug delivery. Richard A. Levy. Oct., p. 16.

DRUG DIVERSION

"Politicization," in Washington Report. James Dickinson. Sept., p. 22.

"Undermining *ethical*," in Washington Report. James Dickinson. Oct., p. 18.

DRUG MARKETING (see also ADVERTISING)

"Another bridge," in Washington Report. James Dickinson. May, p. 20.

"Dirty pool in generics," in Washington Report. James Dickinson. Dec., p. 16.

FDA update: a summary of recent trends in the regulation of drug manufacturing. Daniel L. Michels. March, p. 108.

The good side of side effects. R.A.P. Burt. Nov., p. 20.

A look at OTC buying habits. S.I. Benrimoj. March, p. 24.

No need to apologize. Edward S. Brady. June, p. 18.

"On the goring of oxes," in Washington Report. James Dickinson. March, p. 26.

"Oraflex revisited," in Washington Report. James Dickinson. Nov., p. 22.

Product tampering: an update on minimizing risks. Joel Kushnir, Uma Kastury, and Anthony Shabica. Feb., p. 48.

The unfulfillable promise of safety. John Urquhart, Dec., p. 14.

DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT

"Dirty pool in generics," in Washington Report. James Dickinson. Dec., p. 16.

"Innovator bounce-back," in Washington Report. James Dickinson. April, p. 20.

"Law is a monster," in Washington Report. James Dickinson. Feb., p. 18.

"Revolution, not evolution," in Washington Report. James Dickinson. Jan., p. 18.

ENANTIOMERS

The resolution of enantiomeric drugs using HPLC chiral stationary phases. Thomas D. Doyle and Irving W. Wainer. Feb., p. 28.

ENGINEERING
Design and operation of an aseptic filling system. D.P. Stockdale. May, p. 38.
Electrical design in clean rooms. M. Kaul. Dec., p. 40.
Electrical specifications for pharmaceutical manufacturing equipment. Edward Roeloffs. Jan., p. 32.
Pneumatic logic systems and their application in the pharmaceutical industry. R.J. Smith. Feb., p. 34.
Proper maintenance: a key to product quality. William J. Mead. Oct., p. 42.

EXCIPIENTS
Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.
Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.
Factors influencing migration during spheronization. Te-yen Chien and Noel O. Nuessle. April, p. 42.
Tableting properties of a new protein/lactose/mineral complex. Anand R. Baichwal and Ralph F. Shangraw. Sept., p. 44.

FACILITIES
Design and operation of an aseptic filling system. D.P. Stockdale. May, p. 38.
Electrical design in clean rooms. M. Kaul. Dec., p. 40.
Electrical specifications for pharmaceutical manufacturing equipment. Edward Roeloffs. Jan., p. 32.
FDA update: a summary of recent trends in the regulation of drug manufacturing. Daniel L. Michels. March, p. 108.
Proper maintenance: a key to product quality. William J. Mead. Oct., p. 42.

FILMS
Coated pellets under the microscope. Atul M. Mehta and David M. Jones. June, p. 52.
Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.
Scale-up of film coating processes. Ralph Pondell. June, p. 68.

FLUID-BED TECHNOLOGY
Coated pellets under the microscope. Atul M. Mehta and David M. Jones. June, p. 52.
Continuous variable-frequency fluid-bed drying of pharmaceutical granulations. T. Köblitz, L. Ehrhardt, and Günter Körblein. March, p. 62.
Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.
Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. A.Y. Gore, D.W. McFarland, and N.H. Batuyios. Sept., p. 114.
An overview of flow regimes in fluidized beds. H. Littman. March, p. 48.
Scale-up of film coating processes. Ralph Pondell. June, p. 68.

FOOD AND DRUG ADMINISTRATION (FDA)
Facing the twenty-first century. Frank E. Young. Jan., p. 16.
"Farewell, Mark Novitch," in Washington Report. James Dickinson. April, p. 20.
FDA guidelines for the inspection of bulk pharmaceutical chemicals. Glenn A. Kelley. Oct., p. 32.
FDA update: a summary of recent trends in the regulation of drug manufacturing. Daniel L. Michels. March, p. 108.
FDA's new action plan. Margaret M. Heckler. Sept., p. 18.
Fundamentals of computer system validation and documentation in the pharmaceutical industry. Norbert R. Kuzel. Sept., p. 60.
"Instability at the top," in Washington Report. James Dickinson. Aug., p. 16.
It's our move. Ken Chapman. May, p. 16.
Process validation concepts for drug products. PMA's Validation Advisory Committee. Sept., p. 78.

STOP METALLIC CONTAMINATION
BARKLEY & DEXTER/LOCK
METALCHEK 9X
INSPECT UP TO 10,000 TABLETS PER MINUTE.
Avoid the risk of costly, damaging litigation and the devastating loss of reputation and business. The Metalchek 9X is regarded by many of the world's leading pharmaceutical companies as the standard of the industry for the inspection, detection and automatic rejection of metal contaminated tablets and capsules. Contact us today for complete information on the Metalchek 9X... "The One That Works"

Barkley & Dexter Laboratories, Inc.
207 Authority Drive, P.O. Box 307
231 Industrial Park
Fitchburg, MA 01420-0307
(617) 343-3716 Telex 710-347-6394

Circle Reader Service Card No. 28

GANES
Quality manufacturers of bulk pharmaceuticals and fine chemicals for over 50 years

PHENYLEPHRINE – BASE & SALTS
ALLOPURINOL
POTASSIUM p-AMINOBENZOATE
AMITRIPTYLINE HCL
PROPOXYPHENE SALTS
BARBITURATES
PSEUDOEPHEDRINE SALTS
ISOXSUPRINE HCL
TRIAMTERENE

Complete Product Brochure available upon request



Call or Write
Ganes Chemicals, Inc.
1114 Avenue of the Americas
New York, N.Y. 10036
(212)391-2580

Circle Reader Service Card No. 29

Research and regulatory programs for products derived from rDNA technology. Philip D. Noguchi and Darrell T. Liu. Oct., p. 48.
The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. PMA's Joint Committee on Bioavailability. June, p. 62.
"Trouble at HHS," in Washington Report. James Dickinson. Dec., p. 16.
Washington Report. Monthly column. Jan.–Dec.
"Young's action plan," in Washington Report. James Dickinson. Oct., p. 18.

FORMULATION

Coated pellets under the microscope. Atul M. Mehta and David M. Jones. June, p. 52.
Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.
Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.
Factors influencing migration during spheronization. Te-yen Chien and Noel O. Nuessle. April, p. 42.
Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. A.Y. Gore, D.W. McFarland, and N.H. Batuyios. Sept., p. 114.
An old source of new drugs. Norman Farnsworth. Aug., p. 14.
Tableting properties of a new protein/lactose/mineral complex. Anand R. Baichwal and Ralph F. Shangraw. Sept., p. 44.
Weighing the costs of novel drug delivery. Richard A. Levy. Oct., p. 16.

GOOD MANUFACTURING PRACTICES (GMPs)

FDA guidelines for the inspection of bulk pharmaceutical chemicals. Glenn A. Kelley. Oct., p. 32.
FDA update: a summary of recent trends in the regulation of drug manufacturing. Daniel L. Michels. March, p. 108.
It's our move. Ken Chapman. May, p. 16.
Product tampering: an update on minimizing risks. Joel Kushnir, Uma Kastury, and Anthony Shabica. Feb., p. 48.
Validation and control concepts for water treatment systems. PMA's Deionized Water Committee. Nov., p. 50.

GRANULATION

Continuous variable-frequency fluid-bed drying of pharmaceutical granulations. T. Köblitz, L. Ehrhardt, and Günter Körblein. March, p. 62.
Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.
Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. A.Y. Gore, D.W. McFarland, and N.H. Batuyios. Sept., p. 114.
An overview of flow regimes in fluidized beds. H. Littman. March, p. 48.
Soft gelatin capsules: a solution to many tableting problems. H. Seager. Sept., p. 84.

INSPECTIONS

FDA guidelines for the inspection of bulk pharmaceutical chemicals. Glenn A. Kelley. Oct., p. 32.
Fundamentals of computer system validation and documentation in the pharmaceutical industry. Norbert R. Kuzel. Sept., p. 60.
It's our move. Ken Chapman. May, p. 16.

INSTRUMENTATION

Pneumatic logic systems and their application in the pharmaceutical industry. R.J. Smith. Feb., p. 34.
The use of instrumentation in tablet research, development, and production. Trevor M. Jones, A.Y.K. Ho, and J.F. Barker. March, p. 42.

INVESTIGATIONAL NEW DRUGS (INDs)

FDA's new action plan. Margaret M. Heckler. Sept., p. 18.

HIGH PURITY WATER DESERVES HIGH QUALITY STORAGE

Design Parameters for WFI Storage Vessels Require the Consideration of:

- Vessel Volume
- Pressure Rating
- Corrosion Resistance
- Temperature Maintenance
- Sanitary Components
- Quality



DCI can provide criteria for evaluating materials, surface finishes, insulation, and overall design and construction of WFI storage vessels. Write or call today for your WFI storage tank brochure.

dci INC
600 North 54th Avenue
St. Cloud, MN 56301
612-252-8200

Manufacturing a wide range of stainless steel vessels for Pharmaceutical processing.

Circle Reader Service Card No. 30

LABELING
"Oraflex revisited," in Washington Report. James Dickinson. Nov., p. 22.
Sources of particulate contamination in sterile packaging. D.A. Dean. Aug., p. 32.

LUBRICANTS
Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.
Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.

MEDICAID
"In defense of AWP," in Washington Report. James Dickinson. Aug., p. 16.
Weighing the costs of novel drug delivery. Richard A. Levy. Oct., p. 16.

MICROBIOLOGY
A method for the production of *Clostridium sporogenes* PA 3679 spores on solid medium. Peter K. Chu and Frank J. Marino. Dec., p. 36.
Validation and control concepts for water treatment systems. PMA's Deionized Water Committee. Nov., p. 50.

MICROCAPSULES
Biomaterials: new perspectives on their use in the controlled delivery of polypeptides. Robert Langer. Oct., p. 35.
The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.

MODELS
Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. Mark E. Lacy, Priscilla J. Davis, Earl S. Johnson, and Ann P. Koester. March, p. 98.
Factors influencing migration during spheronization. Te-yen Chien and Noel O. Nuessle. April, p. 42.
Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.
Nonisothermal stability testing. Ian Tucker. May, p. 68.
An overview of flow regimes in fluidized beds. H. Littman. March, p. 48.

NATIONAL ASSOCIATION OF PHARMACEUTICAL MANUFACTURERS (NAPM)
"Law is a monster," in Washington Report. James Dickinson. Feb., p. 18.

NATIONAL ASSOCIATION OF RETAIL DRUGGISTS (NARD)
"On the goring of oxes," in Washington Report. James Dickinson. March, p. 26.
"Ouster of NARD's Woods," in Washington Report. James Dickinson. Jan., p. 18.
"Pharmacy's growing power," in Washington Report. James Dickinson. Aug., p. 16.

NATIONAL PHARMACEUTICAL COUNCIL (NPC)
No need to apologize. Edward S. Brady. June, p. 18.

NEW DRUG APPLICATIONS (NDAs)
FDA update: a summary of recent trends in the regulation of drug manufacturing. Daniel L. Michels. March, p. 108.
FDA's new action plan. Margaret M. Heckler. Sept., p. 18.
"Law is a monster," in Washington Report. James Dickinson. Feb., p. 18.
"NDA rewrite final," in Washington Report. James Dickinson. May, p. 20.
"Revolution, not evolution," in Washington Report. James Dickinson. Jan., p. 18.
"Trouble at HHS," in Washington Report. James Dickinson. Dec., p. 16.



SPL is the only supplier you'll ever need for quality, animal-derived bulk, pharmaceutical and diagnostic products—heparin, pancreatin and blood products.

"You have my word on it."

William E. Melby
President

SPL **Scientific Protein Laboratories**
Division of VIOBIN Corporation
700 E. Main Street
Waunakee, WI 53597
1-608-849-5944

Circle Reader Service Card No. 32

FINE EMULSIONS DISPERSIONS

MICROFLUIDIZERS™
FOR PRODUCTION



- Small uniform particles produced
- Custom designs for special process requirements
- Free evaluation of your samples
- Complete size range—bench scale through production

Throughput to 20 g.p.m. available
—larger units under design.

Microfluidics Corporation
a division of Biotechnology Development Corporation
44 Mechanic St., Newton, MA 02164 Telex 755709

Circle Reader Service Card No. 35

Quality Control from Stiefel— it's assure thing.

It's Assurance. Assurance that the integrity of your product means as much to us as it does to you. Assurance that your product test results will stand up to the closest scrutiny, because they already have . . . before they ever left our lab.

When you need Quality Control Assurance, call us.

- ***Chemical Analyses***
- ***USP/NF Testing***
- ***Physical Analyses***
- ***Product Development***
- ***Microbiological Analyses***
- ***Stability Studies***
- ***Consulting Services***

Phone or write Lance Haskin today for more information.

Stiefel Research Institute

Oak Hill, NY 12460 / 518-239-6901

Circle Reader Service Card No. 36

OSMOTIC DRUG DELIVERY
The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.

OTCs
"FDA'S OTC sidestep," in Washington Report. James Dickinson. Feb., p. 18.
A look at OTC buying habits. S.I. Benrimoj. March, p. 24.
"On the goring of oxes," in Washington Report. James Dickinson. March, p. 26.

PACKAGING
Design and operation of an aseptic filling system. D.P. Stockdale. May, p. 38.
Electron-beam sterilization and its application to aseptic packaging. I.J. Rangwalla, P.M. Fletcher, K.E. Williams, and S.V. Nablo. Nov., p. 36.
Product tampering: an update on minimizing risks. Joel Kushnir, Uma Kastury, and Anthony Shabica. Feb., p. 48.
Sources of particulate contamination in sterile packaging. D.A. Dean. Aug., p. 32.

PARTICULATES
Continuous variable-frequency fluid-bed drying of pharmaceutical granulations. T. Köblitz, L. Ehrhardt, and Günter Körblein. March, p. 62.
Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.
Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.
Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.
An overview of flow regimes in fluidized beds. H. Littman. March, p. 48.
Sources of particulate contamination in sterile packaging. D.A. Dean. Aug., p. 32.

PATENTS
"Law is a monster," in Washington Report. James Dickinson. Feb., p. 18.

PATIENT EDUCATION
A look at OTC buying habits. S.I. Benrimoj. March, p. 24.
No need to apologize. Edward S. Brady. June, p. 18.
The unfulfillable promise of safety. John Urquhart. Dec., p. 14.
Weighing the costs of novel drug delivery. Richard A. Levy. Oct., p. 16.

PERSONNEL
The coming crisis in pharmaceutical development. Robert S. Joslin. Dec., p. 48.
Design and operation of an aseptic filling system. D.P. Stockdale. May, p. 38.
Product tampering: an update on minimizing risks. Joel Kushnir, Uma Kastury, and Anthony Shabica. Feb., p. 48.
Proper maintenance: a key to product quality. William J. Mead. Oct., p. 42.

PHARMACEUTICAL INDUSTRY
The coming crisis in pharmaceutical development. Robert S. Joslin. Dec., p. 48.
Development of an automation plan for a pharmaceutical manufacturing plant. Kevyn Renner. Dec., p. 24.
Facing the twenty-first century. Frank E. Young. Jan., p. 16.
FDA's new action plan. Margaret M. Heckler. Sept., p. 18.
The good side of side effects. R.A.P. Burt. Nov., p. 20.
It's time for some good news about drugs. C. Joseph Stetler. April, p. 16.
A look at OTC buying habits. S.I. Benrimoj. March, p. 24.
No need to apologize. Edward S. Brady. June, p. 18.
An old source of new drugs. Norman Farnsworth. Aug., p. 14.

STATE-OF-THE-ART LYOPHILIZATION SEMINAR

NEW—COMPLETELY REVISED

Recently presented for the British Parenteral Society in Birmingham, England

THE SEAPOINT HOTEL - SAN DIEGO, CA
FEBRUARY 11, 12, 13, 1986

Seminar Contents:

- Introduction
- Product formulation
- Water
- Matrix formulation
- Phase changes
- Thermal analysis
- Freezing of formulation
- Primary drying phase
- Secondary drying phase
- Product properties
- Vacuum technology
- Closure-container system
- and Vacuum Freeze Drying Equipment

Fee $685.00 per person ($600 @ for 3 or more) includes bound seminar notes, luncheons and coffee breaks

Seminar limited to the first 20 to register

For your free brochure and application form, call

(215) 667-2896 or write:

T. A. JENNINGS ASSOCIATES, INC.
P. O. Box 527
Bala Cynwyd, PA 19004

TABLET MANUFACTURERS:
For directly compressible formulations of

CALCIUM CARBONATE

or

OYSTER SHELL

Contact MPT, Specialists in powder bulk processing.

For immediate delivery or general information, call (201) 279-4132

MPT

The powder bulk processing specialists.

Materials Processing Technology, Inc.
95 Prince St., Paterson, NJ 07501 (201) 279-4132
Division of PHARMACONTROL CORP.

Circle Reader Service Card No. 39

"On the goring of oxes," in Washington Report. James Dickinson. March, p. 26.
Product tampering: an update on minimizing risks. Joel Kushnir, Uma Kastury, and Anthony Shabica. Feb., p. 48.
The unfulfillable promise of safety. John Urquhart. Dec., p. 14.

PHARMACEUTICAL MANUFACTURERS ASSOCIATION (PMA)
"Innovator bounce-back," in Washington Report. James Dickinson. April, p. 20.
It's our move. Ken Chapman. May, p. 16.
No need to apologize. Edward S. Brady. June, p. 18.
"Pharmacy's growing power," in Washington Report. James Dickinson. Aug., p. 16.
"User fees," in Washington Report. James Dickinson. Feb., p. 18.

PHARMACEUTICAL TECHNOLOGY
Coated pellets under the microscope. Atul M. Mehta and David M. Jones. June, p. 52.
Continuous variable-frequency fluid-bed drying of pharmaceutical granulations. T. Köblitz, L. Ehrhardt, and Günter Körblein. March, p. 62.
Electron-beam sterilization and its application to aseptic packaging. I.J. Rangwalla, P.M. Fletcher, K.E. Williams, and S.V. Nablo. Nov., p. 36.
Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.
Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. A.Y. Gore, D.W. McFarland, and N.H. Batuyios. Sept., p. 114.
Process validation concepts for drug products. PMA's Validation Advisory Committee. Sept., p. 78.
Scale-up of film coating processes. Ralph Pondell. June, p. 68.
The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.

POLYMERS
Biomaterials: new perspectives on their use in the controlled delivery of polypeptides. Robert Langer. Oct., p. 35.
Chromatographic purification of biopolymers. Fred E. Regnier. Aug., p. 26.
Controlled release of macromolecules from silicone elastomer. Dean S.T. Hsieh, C.C. Chiang, and D.S. Desai. June, p. 39.
The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.

POWDERS
Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.
Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.
Hard gelatin capsules and the pharmaceutical formulator. B.E. Jones. Sept., p. 106.
Soft gelatin capsules: a solution to many tableting problems. H. Seager. Sept., p. 84.
Tableting properties of a new protein/lactose/mineral complex. Anand R. Baichwal and Ralph F. Shangraw. Sept., p. 44.

PROCESS CONTROL
Automation: a retrospective look. David J. Fraade. Feb., p. 16.
Development of an automation plan for a pharmaceutical manufacturing plant. Kevyn Renner. Dec., p. 24.
Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. A.Y. Gore, D.W. McFarland, and N.H. Batuyios. Sept., p. 114.
Fundamentals of computer system validation and documentation in the pharmaceutical industry. Norbert R. Kuzel. Sept., p. 60.
Pneumatic logic systems and their application in the pharmaceutical industry. R.J. Smith. Feb., p. 34.
Process validation concepts for drug products. PMA's Validation Advisory Committee. Sept., p. 78.

CUSTOM
ENCAPSULATION/AGGLOMERATION
SERVICES

PHYSICAL

- Water Soluble Coatings
- Water Insoluble Coatings
- Wide Range of Particle Sizes

FUNCTION

- Timed Release
- Temperature Release
- Agglomeration

Contact: Karen Lynch (216) 344-8797

SCM DURKEE FOODS
DIVISION OF SCM CORPORATION

Circle Reader Service Card No. 41

PHARMACEUTICAL TECHNOLOGY

REPRINT SERVICE

Enhance the value of information programs through the use of papers published in *Pharmaceutical Technology*.

- Training and educating sales and marketing staff
- Content information for industry seminars and conferences
- Informative literature for product users
- Collateral material for classroom text

Volume orders (minimum of 250 copies) of all previous and future articles in *Pharmaceutical Technology* are available exclusively through:

PUBLISHERS DATA CORPORATION
320 N. A St.
P.O. Box 50
Springfield, OR 97477
(503) 726-1211

Circle Reader Service Card No. 42

The use of instrumentation in tablet research, development, and production. Trevor M. Jones, A.Y.K. Ho, and J.F. Barker. March, p. 42.
Validation and control concepts for water treatment systems. PMA's Deionized Water Committee. Nov., p. 50.

PROCESS DEVELOPMENT
Design and operation of an aseptic filling system. D.P. Stockdale. May, p. 38.
Development of an automation plan for a pharmaceutical manufacturing plant. Kevyn Renner. Dec., p. 24.
Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.
Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.
Factors influencing migration during spheronization. Te-yen Chien and Noel O. Nuessle. April, p. 42.
Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. A.Y. Gore, D.W. McFarland, and N.H. Batuyios. Sept., p. 114.
Scale-up of film coating processes. Ralph Pondell. June, p. 68.
The use of instrumentation in tablet research, development, and production. Trevor M. Jones, A.Y.K. Ho, and J.F. Barker. March, p. 42.

PROPRIETARY ASSOCIATION (PA)
A look at OTC buying habits. S.I. Benrimoj. March, p. 24.
"On the goring of oxes," in Washington Report. James Dickinson. March, p. 26.

PURIFICATION
Chromatographic purification of biopolymers. Fred E. Regnier. Aug., p. 26.

QUALITY ASSURANCE/QUALITY CONTROL
Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. Mark E. Lacy, Priscilla J. Davis, Earl S. Johnson, and Ann P. Koester. March, p. 98.
Concepts for reprocessing drug products. PMA's Reprocessing Committee. Sept., p. 127.
A method for the production of *Clostridium sporogenes* PA 3679 spores on solid medium. Peter K. Chu and Frank J. Marino. Dec., p. 36.
Product tampering: an update on minimizing risks. Joel Kushnir, Uma Kastury, and Anthony Shabica. Feb., p. 48.
Proper maintenance: a key to product quality. William J. Mead. Oct., p. 42.
The resolution of enantiomeric drugs using HPLC chiral stationary phases. Thomas D. Doyle and Irving W. Wainer. Feb., p. 28.
The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. PMA's Joint Committee on Bioavailability. June, p. 62.
Scale-up of film coating processes. Ralph Pondell. June, p. 68.
Sources of particulate contamination in sterile packaging. D.A. Dean. Aug., p. 32.

REGULATIONS
Concepts for reprocessing drug products. PMA's Reprocessing Committee. Sept., p. 127.
Facing the twenty-first century. Frank E. Young. Jan., p. 16.
FDA update: a summary of recent trends in the regulation of drug manufacturing. Daniel L. Michels. March, p. 108.
FDA's new action plan. Margaret M. Heckler. Sept., p. 18.
It's our move. Ken Chapman. May, p. 16.
"Oraflex revisited," in Washington Report. James Dickinson. Nov., p. 22.
Research and regulatory programs for products derived from rDNA technology. Philip D. Noguchi and Darrell T. Liu. Oct., p. 48.
Washington Report. Monthly column. Jan.–Dec.

REPROCESSING
Concepts for reprocessing drug products. PMA's Reprocessing Committee. Sept., p. 127.

Hotpack
• A HEINICKE COMPANY



CO_2 INCUBATORS 6.0 to 33 cu. ft. capacity. Solid state control and LED display of temperature, humidity and CO_2. Features self-decontamination cycle. Walk-in, benchtop, floor models. Temperatures from ambient + 5°C to 60°C ±0.1°, humidity from 70% to 95% ±2% and CO_2 from 0% to 20% ±0.1%. Multi-gas option available. Also, many other types of incubators.

Hotpack CO_2 incubators with self-decontamination save time and effort

Independent lab test prove Hotpack CO_2 incubators' decontamination cycle achieves 7 log reduction in B. Stearothermophilus spores, as required for FDA sterilization standards. Decon cycle does it automatically between test runs. Get this exclusive Hotpack feature plus more. Call Hotpack today for your *FREE* literature packet.

Hotpack *works*...with *you*...direct. Custom systems? Modifications? We'll engineer to *your* needs. Call us *toll free*

800-523-3608

or 215-824-1700 in Pennsylvania

Hotpack Corporation 10940 Dutton Rd. Philadelphia, PA 19154 • Telex 685-1197

Circle Reader Service Card No. 44

QO® METHYLFURAN



QO® 2-Methylfuran is a cyclic, dienic ether. The polyfunctionality of Methylfuran makes it a versatile chemical intermediate. Methylfuran undergoes diene, nuclear substitution, ring opening, and other reactions.

For additional information and/or samples, contact:

QO Chemicals, Inc.
823 Commerce Drive
Oak Brook, Illinois 60521
Telephone: (312) 850-2378

QO CHEMICALS

Circle Reader Service Card No. 45

RESEARCH AND DEVELOPMENT

Controlled release of macromolecules from silicone elastomer. Dean S.T. Hsieh, C.C. Chiang, and D.S. Desai. June, p. 39.

Factors influencing migration during spheronization. Te-yen Chien and Noel O. Nuessle. April, p. 42.

It's time for some good news about drugs. C. Joseph Stetler. April, p. 16.

Nonisothermal stability testing. Ian Tucker. May, p. 68.

Research and regulatory programs for products derived from rDNA technology. Philip D. Noguchi and Darrell T. Liu. Oct., p. 48.

The use of instrumentation in tablet research, development, and production. Trevor M. Jones, A.Y.K. Ho, and J.F. Barker. March, p. 42.

Rx-TO-OTC SWITCH (see OTCs)

SAMPLING

Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. Mark E. Lacy, Priscilla J. Davis, Earl S. Johnson, and Ann P. Koester. March, p. 98.

SCALE-UP

Factors to consider in fluid-bed processing. David M. Jones. April, p. 50.

Fluid-bed granulation: factors affecting the process in laboratory development and production scale-up. A.Y. Gore, D.W. McFarland, and N.H. Batuyios. Sept., p. 114.

Scale-up of film coating processes. Ralph Pondell. June, p. 68.

SCANNING ELECTRON MICROGRAPHS (SEMs)

Coated pellets under the microscope. Atul M. Mehta and David M. Jones. June, p. 52.

Drug-excipient interactions resulting from powder mixing, I: possible mechanism of interaction with starch and its effect on drug dissolution. Z.T. Chowhan and Li-hua Chi. March, p. 84.

Drug-excipient interactions resulting from powder mixing, II: possible mechanism of interaction with crospovidone and its effect on in vitro dissolution. Z.T. Chowhan and Li-hua Chi. April, p. 28.

Tableting properties of a new protein/lactose/mineral complex. Anand R. Baichwal and Ralph F. Shangraw. Sept., p. 44.

SENSORS

Automation: a retrospective look. David J. Fraade. Feb., p. 16.

"Process control and the computer," in Computerspeak. N.R. Anderson. Dec., p. 20.

SPECIAL PUBLICATIONS

Buyer's Guide. July.

Index to *Pharmaceutical Technology*, Vol. 8 (Jan. 1984 to Dec. 1984). Jan., p. 40.

Pharm Tech Conference '85 abstracts. Aug., p. 38.

Pharm Tech Conference '85 report. Nov., p. 58.

STABILITY

Nonisothermal stability testing. Ian Tucker. May, p. 68.

Soft gelatin capsules: a solution to many tableting problems. H. Seager. Sept., p. 84.

Sources of particulate contamination in sterile packaging. D.A. Dean. Aug., p. 32.

STANDARDS

Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. Mark E. Lacy, Priscilla J. Davis, Earl S. Johnson, and Ann P. Koester. March, p. 98.

The resolution of enantiomeric drugs using HPLC chiral stationary phases. Thomas D. Doyle and Irving W. Wainer. Feb., p. 28.

"USP's importance," in Washington Report. James Dickinson. June, p. 20.

STATISTICS

Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. Mark E. Lacy, Priscilla J. Davis, Earl S. Johnson, and Ann P. Koester. March, p. 98.

Factors influencing migration during spheronization. Te-yen Chien and Noel O. Nuessle. April, p. 42.

If it's Direct Compression you want...WE'VE GOT IT!

Direct Compression —
- ACETAMINOPHEN
- B-50
- MANNITOL
- OYSTER SHELL
- YEAST

...and a lot more!

For problem-solving info about any Direct Compression project, call THE EXPERTS...

AMERICAN ROLAND CHEMICAL CORPORATION

100 FAIRCHILD AVENUE, PLAINVIEW, NY 11803
TELEPHONE: 516-349-8500 • TELEX: 232771
Serving the Pharmaceutical, Food, Feed & Chemical Industry since 1940.

Circle Reader Service Card No. 47

Have You Considered the Services of a Recruitment Specialist?

In the pharmaceutical, medical devices and diagnostic industries, Kalvert Personnel is the recognized recruitment specialist servicing both the company and the candidate.

Through special screening and evaluation techniques we have developed a leading reputation among the members of the pharmaceutical, medical devices and diagnostic fraternity, and the results are most gratifying to the companies we service and the candidates we recommend.

INDUSTRIES WE SERVICE

• PHARMACEUTICAL (Ethical/Proprietary—otc/Veterinary) • BULK PRODUCTS • BIOLOGICS • THERAPEUTICS • GENERICS • CLINICAL & DIAGNOSTIC PRODUCTS • MEDICAL DEVICES • GENETIC ENGINEERING • COSMETICS • INSTRUMENT/EQUIPMENT SUPPLIER.

POSITIONS WE RECRUIT

• TECHNICAL/BIOLOGICAL & CHEMICAL (Pharmacologist/Pharmacist/Immunochemist/Analytical/ETC.) • ENGINEERING/OPERATIONS (Process/Manufacturing/Packaging/ETC.) • QUALITY ASSURANCE/CONTROL (Director/Manager/Supervisor/Compliance/ETC.) • REGULATORY AFFAIRS (Submissions/Documentation/ETC.) • CLINICAL RESEARCH • STERILIZATION/MICROBIOLOGIST • MANUFACTURING/MATERIALS (Director/Plant Manager/Manager/Supervisor/ETC.) • MARKETING (VP/Director/Manager/Product Manager/Business Development/ETC.)

All fees and expenses paid by company.
Call Leonard Kalvert at (516) 348-1500
Or send resume, in confidence, to:

KALVERT

PERSONNEL SERVICE, INC.
ESTABLISHED 1966
P.O. Box Q, Dept. PT, Deer Park, L.I., NY 11729

Circle Reader Service Card No. 48

The unfulfillable promise of safety. John Urquhart. Dec., p. 14.

STERILE OPERATIONS
Design and operation of an aseptic filling system. D.P. Stockdale. May, p. 38.
Electron-beam sterilization and its application to aseptic packaging. I.J. Rangwalla, P.M. Fletcher, K.E. Williams, and S.V. Nablo. Nov., p. 36.

STERILIZATION
Electron-beam sterilization and its application to aseptic packaging. I.J. Rangwalla, P.M. Fletcher, K.E. Williams, and S.V. Nablo. Nov., p. 36.
A method for the production of *Clostridium sporogenes* PA 3679 spores on solid medium. Peter K. Chu and Frank J. Marino. Dec., p. 36.
Sources of particulate contamination in sterile packaging. D.A. Dean. Aug., p. 32.
Validation and control concepts for water treatment systems. PMA's Deionized Water Committee. Nov., p. 50.

TABLETS AND TABLETING
Acquiring and using data in studies of compaction. Robert P. Giannini. Feb., p. 44.
Comparison of tablet and capsule weight-variation criteria by Monte Carlo simulation. Mark E. Lacy, Priscilla J. Davis, Earl S. Johnson, and Ann P. Koester. March, p. 98.
Soft gelatin capsules: a solution to many tableting problems. H. Seager. Sept., p. 84.
Tableting properties of a new protein/lactose/mineral complex. Anand R. Baichwal and Ralph F. Shangraw. Sept., p. 44.
The use of instrumentation in tablet research, development, and production. Trevor M. Jones, A.Y.K. Ho, and J.F. Barker. March, p. 42.

TESTING
Acquiring and using data in studies of compaction. Robert P. Giannini. Feb., p. 44.
Nonisothermal stability testing. Ian Tucker. May, p. 68.
The role of dissolution testing in drug quality, bioavailability, and bioequivalence testing. PMA's Joint Committee on Bioavailability. June, p. 62.

TRAINING
Automation: a retrospective look. David J. Fraade. Feb., p. 16.
The coming crisis in pharmaceutical development. Robert S. Joslin. Dec., p. 48.

UNITED STATES PHARMACOPEIA
"USP's importance," in Washington Report. James Dickinson. June, p. 20.

USER FEES
"Innovator bounce-back," in Washington Report. James Dickinson. April, p. 20.
"User fees," in Washington Report. James Dickinson. Feb., p. 18.

VALIDATION
Fundamentals of computer system validation and documentation in the pharmaceutical industry. Norbert R. Kuzel. Sept., p. 60.
It's our move. Ken Chapman. May, p. 16.
Process validation concepts for drug products. PMA's Validation Advisory Committee. Sept., p. 78.
Validation and control concepts for water treatment systems. PMA's Deionized Water Committee. Nov., p. 50.

VETERINARY DRUGS
The use of biocompatible polymers in rate-controlled drug delivery systems. Yie W. Chien. May, p. 50.
"Veterinary trade-off," in Washington Report. James Dickinson. March, p. 26.

WATER
Validation and control concepts for water treatment systems. PMA's Deionized Water Committee. Nov., p. 50.